




RealRate

# PHARMACEUTICAL 2022

CHINA PHARMA HOLDINGS INC.  
Rank 175 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of CHINA PHARMA HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINA PHARMA HOLDINGS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 195% points. The greatest weakness of CHINA PHARMA HOLDINGS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is -34%, being 242% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	9,093
Cost of Goods Sold	9,293
Intangible Assets	148
Liabilities, Current	10,513
Liabilities, Non-Current	44
Other Assets	128
Other Compr. Net Income	218
Other Expenses	1,240
Other Liabilities	6,074
Other Net Income	-539
Property and Equipment	13,281
Research and Development	319
Revenues	9,642
Selling, General and Administrative Expense	1,651

Output Variable	Value in 1000 USD
Assets	22,650
Liabilities	16,632
Expenses	12,502
Stockholders Equity	6,018
Net Income	-3,399
Comprehensive Net Income	-3,290
Economic Capital Ratio	-34%